Prostascint (111In-Capromab Pendetide) (CYT-356)

Scott Williams
Apr 2, 2002

Prostascint (111In-Capromab Pendetide) (CYT-356)

Clinical problem

Chemistry and pharmacology

Imaging Protocol

Interpretation

Indications for the exam

Dosimetry

Complications/Side Effects

HAMA Formation (Immunogenicity)

Latest in Tumor Imaging
Tumor > Therapy > Xofigo and other Prostate Agents
August 16, 2017
Tumor > Therapy > Xofigo and PSMA therapies
January 26, 2015
My BreastAI Suite by GE HealthCare
Sponsored
My BreastAI Suite by GE HealthCare
April 2, 2024
Coronal Ct
Tumor > Therapy > Microspheres
January 31, 2008
Related Stories
Mr Brain Tumor
Tumor Imaging
Thallium Tumor Imaging:
Figure 1
Tumor Imaging
Introduction
/ScottWilliamsMD2/NucMed/Tumor/CEA-scan/Cytogen%20cases/pet1.jpg (1203 bytes)
Tumor Imaging
Tumor > CEA-scan > Cytogen cases
My BreastAI Suite by GE HealthCare
Sponsor Content
My BreastAI Suite by GE HealthCare
More in Tumor Imaging
Tumor > Therapy > Xofigo and other Prostate Agents
By Scott Williams
August 16, 2017
Tumor > Therapy > Xofigo and PSMA therapies
By Scott Williams
January 26, 2015
Tumor > Octreotide
By Scott Williams
October 31, 2010
Tumor > Therapy > Microspheres
By Scott Williams
January 31, 2008
Coronal Ct
Tumor > Neotect
By Scott Williams
February 19, 2007
Neotect F
Tumor > Sestamibi
By Scott Williams
April 2, 2002
Tumor > Therapy > P32
By Scott Williams
April 2, 2002
[In-111-DTPA-D-Phe-] Octreotide:
By Scott Williams
April 2, 2002
Prostascint (111In-Capromab Pendetide) (CYT-356)
By Scott Williams
April 2, 2002
Whole Body
Gallium 67 Tumor Imaging
By Scott Williams
April 2, 2002
Tumor > Prostascint
By Scott Williams
April 2, 2002
Tc-99m-Arcitumomab (CEA-Scan)
By Scott Williams
April 2, 2002
Page 1 of 6
Next Page